Corbus Pharmaceuticals Holdings, Inc. reported financial results for the fiscal quarter ended September 30, 2026, alongside updates on its clinical development programs. The company announced that it has dosed the first patient in the TEMPO-1 registrational study of its drug candidate sutantatug envedotin (CRB-701) for patients with previously treated oropharyngeal cancer. TEMPO-1 is a randomized, controlled study enrolling 250 patients, comparing the antibody drug conjugate to investigators' choice of capecitabine, cetuximab, or docetaxel. The primary endpoint for potential accelerated approval is objective response rate, while overall survival is the primary endpoint for full approval. The company also disclosed that it received FDA clearance in July 2026 to proceed with the TEMPO-1 study.
In the obesity space, Corbus reported topline data from the CANYON-1 Phase 1b study of CRB-913. The trial enrolled 254 obese, non-diabetic adults at multiple U.S. sites. Participants received daily doses of 20 mg, 40 mg, or 60 mg of CRB-913, or placebo, for 12 weeks. The data demonstrated statistically significant weight loss at all three doses, with the 60 mg dose achieving a mean weight loss of 5% after 12 weeks. The company noted that no plateau was observed at any dose and that CRB-913 was associated with a favorable safety profile and fewer gastrointestinal adverse events compared to marketed oral GLP-1 drugs. Late-breaking data from this study is scheduled to be presented at ObesityWeek 2026 on November 15, 2026.
Regarding its leadership, Corbus announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer in August 2026. Dr. Nicacio brings over 20 years of experience in pharmaceutical industry leadership roles at companies including Protara Therapeutics, AstraZeneca, and Sanofi.
Financially, for the three months ended September 30, 2026, the company reported a net loss of approximately $37.8 million, or $1.81 per share. This compares to a net loss of approximately $23.3 million, or $1.90 per share, for the same period in the prior year. Total operating expenses increased by $14.4 million to approximately $38.8 million, driven by a $15.0 million development milestone incurred pursuant to the licensing agreement with CSPC Megalith Biopharmaceutical Co. Ltd. for sutantatug envedotin. As of September 30, 2026, the company held $115.3 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028 based on current operating plans.
